Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder | Zendy

Evdokia Anagnostou | Zendy; Michael G. Aman | Zendy; Benjamin L. Handen | Zendy; Kevin Sanders | Zendy; Amy M. Shui | Zendy; Jill A. Hollway | Zendy; Jessica Brian | Zendy; L. Eugene Arnold | Zendy; Lucia Capano | Zendy; Jessica A. Hellings | Zendy; Eric Butter | Zendy; Deepali Mankad | Zendy; Rameshwari V. Tumuluru | Zendy; Jessica Candelora Kettel | Zendy; Cassandra R. Newsom | Zendy; Stasia Hadjiyannakis | Zendy; Naomi Peleg | Zendy; Dina Odrobina | Zendy; Sarah McAuliffe-Bellin | Zendy; Pearl Zakroysky | Zendy; Sarah Marler | Zendy; Alexis Wagner | Zendy; Taylor Wong | Zendy; Eric A. Macklin | Zendy; Jeremy VeenstraVanderWeele | Zendy

Open Access

Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder

Author(s) -

Evdokia Anagnostou,

Michael G. Aman,

Benjamin L. Handen,

Kevin Sanders,

Amy M. Shui,

Jill A. Hollway,

Jessica Brian,

L. Eugene Arnold,

Lucia Capano,

Jessica A. Hellings,

Eric Butter,

Deepali Mankad,

Rameshwari V. Tumuluru,

Jessica Candelora Kettel,

Cassandra R. Newsom,

Stasia Hadjiyannakis,

Naomi Peleg,

Dina Odrobina,

Sarah McAuliffe-Bellin,

Pearl Zakroysky,

Sarah Marler,

Alexis Wagner,

Taylor Wong,

Eric A. Macklin,

Jeremy VeenstraVanderWeele

Publication year - 2016

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2016.1232

Subject(s) - medicine , autism spectrum disorder , risperidone , tolerability , autism , placebo , atypical antipsychotic , irritability , antipsychotic , randomized controlled trial , psychiatry , pediatrics , body mass index , overweight , aripiprazole , adverse effect , anxiety , schizophrenia (object oriented programming) , alternative medicine , pathology

Atypical antipsychotic medications are indicated for the treatment of irritability and agitation symptoms in children with autism spectrum disorder (ASD). Unfortunately, these medications are associated with weight gain and metabolic complications that are especially troubling in children and with long-term use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research